Clinical Investigation Specialists, Inc.

Gurnee, Illinois 60031

1 studies enrolling now · 31 studies all time

What they study most

Acute Coronary Syndrome, Atherosclerosis, Atrial Fibrillation, Atrial Flutter, Blood Pressure, High, Cardiovascular Disease, Cardiovascular Diseases, Chronic Idiopathic Constipation (CIC), Dyslipidemia, Fibromyalgia, Gout, Gout Flare

Studies at this site

• A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults — Recruiting now
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) — Completed
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia — Completed
• Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens — Completed
• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients — Completed
• A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention — Stopped early
• Phase 2 Study of TD-9855 to Treat Fibromyalgia — Completed
• An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). — Completed
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. — Completed
• This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• Study of AC-201 in Patients With Type 2 Diabetes Mellitus — Completed
• A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee — Completed
• Phase III Acute Coronary Syndrome — Stopped early
• Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain — Completed
• Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee — Completed
• Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder — Completed
• Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin — Completed
• Study of Diclofenac Capsules to Treat Osteoarthritis Pain — Completed
• Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain — Completed
• A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine — Completed
• DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension — Stopped early
• DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension — Completed
• Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension — Completed